Could a home device spot heart trouble in childhood cancer survivors?

NCT ID NCT05138991

Ongoing Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a portable, self-administered device that measures heart function in childhood cancer survivors, who are at risk for heart problems from past treatments. Researchers will compare the device's accuracy and ease of use in the clinic and at home against standard hospital tests like echocardiograms and MRIs. The goal is to see if this simpler approach can detect early signs of heart trouble effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SphygmoCor® Xcel and Oscar 2™ ambulatory blood pressure monitor
What this could lead to: If successful, this portable system could allow childhood cancer survivors to easily monitor their heart health at home, catching problems earlier than current methods.
What could go wrong: This is an early-stage study focused on accuracy and reproducibility, not treatment. The device may not prove reliable enough to replace standard hospital tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.